IN2014MN01962A - - Google Patents
Info
- Publication number
- IN2014MN01962A IN2014MN01962A IN1962MUN2014A IN2014MN01962A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A IN 1962MUN2014 A IN1962MUN2014 A IN 1962MUN2014A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A
- Authority
- IN
- India
- Prior art keywords
- cabazitaxel
- crystalline form
- preparation
- novel
- novel crystalline
- Prior art date
Links
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 abstract 6
- 229960001573 cabazitaxel Drugs 0.000 abstract 6
- 238000002360 preparation method Methods 0.000 abstract 3
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 ester compound Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
The present invention relates to the field of medical chemistry and discloses a preparation method for three crystal forms of cabazitaxel that is ester compound crystalline form J of cabazitaxel hydrate crystalline form G of cabazitaxel and crystalline form I of cabazitaxel and a novel crystalline form of cabazitaxel. The novel crystalline form of cabazitaxel according to the invention has good stability and good solubility in commonly used solvents and is easy to be preserved and is stable under treatment during preparation of dosage forms thus could be used for the preparation of drugs for treating prostate cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210259595.3A CN102746258B (en) | 2012-07-25 | 2012-07-25 | Crystal forms of cabazitaxel and preparation method thereof |
| PCT/CN2013/079575 WO2014015760A1 (en) | 2012-07-25 | 2013-07-18 | Crystal form of cabazitaxel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01962A true IN2014MN01962A (en) | 2015-07-10 |
Family
ID=47026807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1962MUN2014 IN2014MN01962A (en) | 2012-07-25 | 2013-07-18 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9353076B2 (en) |
| EP (2) | EP3067348A1 (en) |
| JP (1) | JP6329135B2 (en) |
| CN (1) | CN102746258B (en) |
| AU (2) | AU2013295924B2 (en) |
| CA (2) | CA2909500C (en) |
| IN (1) | IN2014MN01962A (en) |
| WO (1) | WO2014015760A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012142117A1 (en) | 2011-04-12 | 2012-10-18 | Plus Chemicals Sa | Solid state forms of cabazitaxel and processes for preparation thereof |
| US9394266B2 (en) | 2012-03-08 | 2016-07-19 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102746258B (en) | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | Crystal forms of cabazitaxel and preparation method thereof |
| CN103804323A (en) * | 2012-11-14 | 2014-05-21 | 上海希迈医药科技有限公司 | Jevtana solvate and preparation method and application thereof |
| CN103819428B (en) * | 2012-11-19 | 2016-01-13 | 齐鲁制药有限公司 | Crystal formation of the solvate of 7 β, 10 β-dimethoxy docetaxel and preparation method thereof |
| CN103058960B (en) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | Cabazitaxel polymorphic form and preparation method thereof |
| KR101429543B1 (en) | 2012-12-13 | 2014-08-14 | 주식회사 삼양바이오팜 | A novel crystal form of cabazitaxel and a method for preparing the same |
| CN103044364B (en) * | 2013-01-07 | 2016-01-20 | 重庆泰濠制药有限公司 | Amorphous crystalline substance of a kind of Cabazitaxel and preparation method thereof |
| WO2014128728A2 (en) * | 2013-02-25 | 2014-08-28 | Laurus Labs Private Limited | Solid forms of cabazitaxel and processes for preparation thereof |
| CN103450119B (en) * | 2013-09-24 | 2015-06-17 | 天津炜捷制药有限公司 | Cabazitaxel with crystal form W and method for preparing same |
| EP2865674A1 (en) * | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Crystalline solvate forms of Cabazitaxel |
| CN105461665A (en) * | 2014-08-21 | 2016-04-06 | 中国医学科学院药物研究所 | Cabazitaxel N6 crystal form substance, and preparation method, composition and use thereof |
| CN105461664A (en) * | 2014-08-21 | 2016-04-06 | 中国医学科学院药物研究所 | Cabazitaxel N5 crystal form substance, and preparation method, composition and use thereof |
| AU2017207821A1 (en) | 2016-01-15 | 2018-07-19 | Zhuhai Beihai Biotech Co., Ltd. | Compositions and formulations including cabazitaxel and human serum albumin |
| EP3509569A1 (en) * | 2016-09-07 | 2019-07-17 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| CN112055588B (en) | 2018-04-20 | 2023-09-08 | 珠海贝海生物技术有限公司 | Cabazitaxel formulations and compositions |
| CN113429369B (en) * | 2021-07-23 | 2022-12-02 | 无锡紫杉药业有限公司 | Efficient cabazitaxel purification method |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ519984A (en) | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| FR2859996B1 (en) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | ACETONIC SOLVAT OF DIMETHOXY DOCETAXEL AND PROCESS FOR PREPARING THE SAME |
| FR2926551A1 (en) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME |
| CN101525321B (en) * | 2008-03-06 | 2012-03-07 | 上海希迪制药有限公司 | Polyenic taxusol sesquihydrate crystal and preparation method thereof |
| PL388144A1 (en) * | 2009-05-29 | 2010-12-06 | Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością | (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate 4-acetoxy-2?-benzoiloxy-5� ,20-epoxy-1, 7�, 10�-trihydroxy-9-oxo-taks-11 -en-13?-yl solvates, a method for their production and application thereof |
| CN102060815B (en) * | 2010-12-24 | 2012-09-26 | 重庆泰濠制药有限公司 | Preparation method of taxanes compound |
| WO2012142117A1 (en) * | 2011-04-12 | 2012-10-18 | Plus Chemicals Sa | Solid state forms of cabazitaxel and processes for preparation thereof |
| TWI526437B (en) * | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | Crystalline forms of cabazitaxel |
| CN102336726B (en) * | 2011-09-30 | 2014-11-26 | 重庆泰濠制药有限公司 | Method for preparing cabazitaxel |
| US9772339B2 (en) * | 2011-09-30 | 2017-09-26 | Life Technologies Corporation | Methods and systems for image analysis identification |
| CN102503913B (en) * | 2011-10-20 | 2014-03-26 | 江苏红豆杉生物科技股份有限公司 | Preparation method for dimethoxy taxanes compound monocrystal directly used for X-ray single crystal diffraction analysis |
| WO2013065070A1 (en) * | 2011-11-01 | 2013-05-10 | Fresenius Kabi Encology Ltd. | Amorphous form of cabazitaxel and process for its preparation |
| ES2716799T3 (en) * | 2011-11-28 | 2019-06-17 | Fresenius Kabi Oncology Ltd | Crystal form of cabazitaxel and process for the preparation of it |
| EP2791122B1 (en) * | 2011-12-13 | 2019-01-23 | Aventis Pharma S.A. | Crystalline form of cabazitaxel and process for preparing the same |
| US9394266B2 (en) | 2012-03-08 | 2016-07-19 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102746258B (en) | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | Crystal forms of cabazitaxel and preparation method thereof |
| EP2880021A4 (en) * | 2012-07-31 | 2015-06-17 | Yung Shin Pharm Ind Co Ltd | Amorphous cabazitaxel |
| CN102898406B (en) * | 2012-11-02 | 2014-12-03 | 上海金和生物技术有限公司 | Cabazitaxel crystal and preparation method thereof |
| CN103058960B (en) | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | Cabazitaxel polymorphic form and preparation method thereof |
-
2012
- 2012-07-25 CN CN201210259595.3A patent/CN102746258B/en active Active
-
2013
- 2013-07-18 AU AU2013295924A patent/AU2013295924B2/en active Active
- 2013-07-18 US US14/399,513 patent/US9353076B2/en active Active
- 2013-07-18 IN IN1962MUN2014 patent/IN2014MN01962A/en unknown
- 2013-07-18 EP EP16162975.3A patent/EP3067348A1/en not_active Withdrawn
- 2013-07-18 EP EP13822828.3A patent/EP2835369B1/en active Active
- 2013-07-18 CA CA2909500A patent/CA2909500C/en active Active
- 2013-07-18 JP JP2015514346A patent/JP6329135B2/en active Active
- 2013-07-18 CA CA2870569A patent/CA2870569A1/en not_active Abandoned
- 2013-07-18 WO PCT/CN2013/079575 patent/WO2014015760A1/en not_active Ceased
-
2016
- 2016-01-21 AU AU2016200343A patent/AU2016200343B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2909500A1 (en) | 2014-01-30 |
| JP2015518012A (en) | 2015-06-25 |
| CN102746258A (en) | 2012-10-24 |
| AU2016200343A1 (en) | 2016-02-11 |
| EP2835369A1 (en) | 2015-02-11 |
| AU2016200343B2 (en) | 2017-03-30 |
| CA2870569A1 (en) | 2014-01-30 |
| EP2835369A4 (en) | 2015-12-02 |
| AU2013295924B2 (en) | 2016-02-18 |
| CA2909500C (en) | 2018-01-09 |
| US9353076B2 (en) | 2016-05-31 |
| CN102746258B (en) | 2015-02-04 |
| EP2835369B1 (en) | 2019-04-03 |
| EP3067348A1 (en) | 2016-09-14 |
| JP6329135B2 (en) | 2018-05-23 |
| AU2013295924A1 (en) | 2014-10-23 |
| WO2014015760A1 (en) | 2014-01-30 |
| US20150141674A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01962A (en) | ||
| IN2014MN01755A (en) | ||
| MY177994A (en) | Therapeutically active compounds and their methods of use | |
| NZ706739A (en) | Substituted benzene compounds | |
| MX2020010535A (en) | Methods of treating cancer. | |
| EA201592068A1 (en) | INHANSER INHIBITORS ZESTE HOMOLOGIST 2 | |
| NZ739760A (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| NZ715747A (en) | Syk inhibitors | |
| MY178621A (en) | Deuterated cftr potentiators | |
| MX2015008187A (en) | Deuterated alk inhibitors. | |
| CR20200479A (en) | Therapeutically active compounds and their methods of use | |
| MX349159B (en) | Deuterated derivatives of ivacaftor. | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX360634B (en) | Substituted 3-haloallylamine inhibitors of ssao and uses thereof. | |
| PH12016502355B1 (en) | Pharmaceutical composition | |
| MX2014003376A (en) | Benzoic acid derivatives as eif4e inhibitors. | |
| MX347616B (en) | Csf-1r inhibitors for treatment of brain tumors. | |
| TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
| IN2015DN01151A (en) | ||
| NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX2016003522A (en) | Quinazoline derivatives and their use as dna methyltransferase inhibitors. | |
| NZ736970A (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
| MX376029B (en) | Isoindole compounds | |
| IN2013DN02555A (en) | ||
| WO2012112232A8 (en) | METHODS AND COMPOSITIONS FOR TREATING β-THALASSEMIA AND SICKLE CELL DISEASE |